Matching articles for "polatuzumab vedotin"
Issue 1682 · August 7, 2023
Glofitamab (Columvi) for Diffuse Large B-Cell Lymphoma (online only)

Glofitamab-gxbm ( Columvi – Genentech), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for IV treatment of relapsed or refractory diffuse large B-cell lymphoma…

Med Lett Drugs Ther. 2023 Aug 7; 65(1682):e129-30 doi:10.58347/tml.2023.1682b
Glofitamab-gxbm ( Columvi – Genentech), a bispecific CD20-directed CD3 T-cell engager, has received accelerated approval from the FDA for IV treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, or large B-cell lymphoma (LBCL) arising from follicular lymphoma after ≥2 lines of systemic therapy. Accelerated approval was based on response rates and durability of response. Glofitamab is the second T-cell-engaging bispecific antibody to be approved in the US for treatment of DLBCL; epcoritamab-bysp (Epkinly) , which is given subcutaneously, was approved earlier. Unlike epcoritamab, glofitamab is not approved for treatment of high-grade B-cell lymphoma.
Issue 1682 · August 7, 2023 Free
In Brief: Tafasitamab (Monjuvi) for Diffuse Large B-Cell Lymphoma (online only)

Tafasitamab-cxix ( Monjuvi – Morphosys), a CD19-directed cytolytic antibody, has received accelerated approval from the FDA for use in combination with lenalidomide (Revlimid) for treatment of relapsed or…

Med Lett Drugs Ther. 2023 Aug 7; 65(1682):e133 doi:10.58347/tml.2023.1682d
Tafasitamab-cxix ( Monjuvi – Morphosys), a CD19-directed cytolytic antibody, has received accelerated approval from the FDA for use in combination with lenalidomide (Revlimid) for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from low grade lymphoma, in adults who are not eligible for autologous stem cell transplant. Accelerated approval was based on overall response rates.
Issue 1677 · May 29, 2023
Polatuzumab vedotin (Polivy) for Lymphoma (online only)

Polatuzumab vedotin-piiq ( Polivy – Genentech), a CD79b-directed antibody and microtubule inhibitor conjugate, has been approved by the FDA for use in combination with rituximab, cyclophosphamide,…

Med Lett Drugs Ther. 2023 May 29; 65(1677):e89-90 doi:10.58347/tml.2023.1677f
Polatuzumab vedotin-piiq ( Polivy – Genentech), a CD79b-directed antibody and microtubule inhibitor conjugate, has been approved by the FDA for use in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for first-line treatment of diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) in adults who have an International Prognostic Index (IPI) score ≥2. The drug was previously approved for use in combination with bendamustine and rituximab for treatment of patients with relapsed or refactory DLBCL, NOS, who received at least 2 prior therapies.